All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 26, 2021
Home » Blogs » BioWorld Perspectives » Laugh First, Think Later: IG Nobel Prizes Entertain

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Laugh First, Think Later: IG Nobel Prizes Entertain

Sep. 30, 2011
By Anette Breindl
No Comments

What did the productive procrastinator say to the beetle on the beer bottle? “Oh, you won an Ig Nobel Prize, too!”

That’s right. One of my favorite parts of the science awards season has arrived: Yesterday, another crop of Ig Nobel winners was announced.

This year’s crop of Ig Nobel-worthy findings included the fact that yawning is not contagious in turtles; that the best way to procrastinate on something important is to avoid it by doing something else that is also important; and that the problem of illegally parked luxury cars can be solved by running them over with an armored tank, demonstrated rather spectacularly by the mayor of Vilnius. The latter finding, somewhat counter intuitively, received a Peace Prize – I might have guessed economics.

I love the Ig Nobels because they are so very good at what they set out to do: honor research that “first makes people laugh, and then makes them think.”

Really, that’s not bad advice for being effective. Speaking at the Lasker Awards ceremony last week, New York Mayor Michael Bloomberg – who won the public service award – went for laughs in his acceptance speech by dryly noting that public service – in his case in the form of draconian antismoking laws – comes with a lot of pushback for keeping people from trying to kill themselves.

Really, he was making the same point as Vilnius mayor Arturas Zuokas was: to protect what’s best for the public, sometimes you have to be willing to make enemies. (Though I suspect that Bloomberg still has a lot more friends that Zuokas does.)

Another thing about the Ig Nobels that sometimes gets lost in the giggling is that they honor good research. One of last year’s Nobel Prize winners, Andrew Geim, who won the 2010 Nobel Prize in Physics for his experiments on graphene, was an IgNobel winner in 2000, when he and a colleague used magnets to levitate a frog.

On Monday, this year’s Nobel Prize announcements will start, like every year, with the Nobel Prize for physiology and medicine. They will most likely be Lasker winners – almost all of the past 15 years’ Nobelists have been. Maybe it will be Brian Druker, Charles Sawyers, and Nicholas Lyson, the folks who brought us Gleevec. They are Lasker winners, they are predicted as favorites by at least one poll, and they certainly, certainly deserve it.

But in my heart of hearts, I’m hoping for Bart Knols and Ruurd de Jong, 2006 IgNobel winners for their research into the sense of smell of the malaria parasite-carrying Anopheles mosquito.

And one more hint: if you plan to watch the announcement live at around 5:30 a.m. ET come Monday, you might make good use of 2005 Economics winner Gauri Nanda’s invention: “an alarm clock that runs away and hides, repeatedly, thus ensuring that people DO get out of bed, and thus theoretically adding many productive hours to the workday.”

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing